Cargando…

Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.

In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DA-REPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the outcomes of treatment. Multivariable cox-proportional hazard model was used to estimate th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Devi, Kanta, Shaikh, Muhammad Usman, Ali, Natasha Bahadur, Adil, Salman Naseem, Khan, Maria, Soomar, Salman Muhammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648798/ https://www.ncbi.nlm.nih.gov/pubmed/34926144 http://dx.doi.org/10.1016/j.lrr.2021.100284

Ejemplares similares

Response to ifosfamide, carboplatin, etoposide (ICE) vs. dexamethasone, cytarabine cisplatin (DHAP) as salvage chemotherapy in patients with relapsed/refractory lymphoma
por: Devi, Kanta, et al.
Publicado: (2023)

DA-EPOCH-R improves the prognosis of patients with double-expressor lymphoma: A single-center retrospective study and meta-analysis
por: Zhan, Jing, et al.
Publicado: (2022)

Treatment Outcomes and Clinical Relevance in Patients with Double Expressor DLBCL
por: Rungwittayatiwat, Sirapat, et al.
Publicado: (2021)

PB2127: NO IMPACT OF STATIN USE ON RESPONSE AND SURVIVAL RATES IN NEWLY DIAGNOSED DLBCL PATIENTS TREATED WITH R-DA-EPOCH
por: Sabljic, A., et al.
Publicado: (2022)

A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution
por: Huang, Jia-Jia, et al.
Publicado: (2016)

DLBCL 1L—What to Expect beyond R-CHOP?
por: Stegemann, Maike, et al.
Publicado: (2022)

P1178: THE APPLICABILITY OF PROGNOSTIC MODELS UNDER RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): A COMPARISON WITH R-CHOP
por: Vassilakopoulos, Theodoros, et al.
Publicado: (2023)

Five‐year follow‐up of a phase II study of DA‐EPOCH‐R with high‐dose MTX in CD5‐positive DLBCL
por: Miyazaki, Kana, et al.
Publicado: (2023)

Serpentine Supravenous Hyperpigmentation in an HIV Patient Receiving R-CHOP for DLBCL
por: Lancman, Guido, et al.
Publicado: (2018)

Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL
por: Hartert, Keenan T., et al.
Publicado: (2020)

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
por: de Jonge, A. Vera, et al.
Publicado: (2023)

Real world experience of R‐CHOP with or without consolidative radiotherapy vs DA‐EPOCH‐R in the first‐line treatment of primary mediastinal B‐cell lymphoma
por: Chan, Esther Hian Li, et al.
Publicado: (2019)

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies
por: Ayed, Ayed O., et al.
Publicado: (2018)

R-CHOP方案和R-DA-EPOCH方案一线治疗non-GCB型弥漫大B细胞淋巴瘤回顾性研究
Publicado: (2022)

Predictive Value of Interim PET/CT in DLBCL Treated with R-CHOP: Meta-Analysis
por: Sun, Na, et al.
Publicado: (2015)

CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance
por: Qiao, Li-Yan, et al.
Publicado: (2021)

Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL
por: Herrmann, Ken, et al.
Publicado: (2014)

CYCLON and NPM1 Cooperate within an Oncogenic Network Predictive of R-CHOP Response in DLBCL
por: Bouroumeau, Antonin, et al.
Publicado: (2021)

Study on influencing factors of anthracycline-induced subclinical cardiotoxicity in DLBCL patients administered (R)-CHOP
por: Dong, Qian, et al.
Publicado: (2022)

Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement
por: Geng, Hongzhi, et al.
Publicado: (2023)

Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience
por: Abbasi, Abdul Muqtadir, et al.
Publicado: (2022)

Extranucleolar CYCLON Staining Pattern Is Strongly Associated to Relapse/Refractory Disease in R-CHOP–treated DLBCL
por: Bouroumeau, Antonin, et al.
Publicado: (2021)

To reduce the average length of stay of patients who are admitted for DA-EPOCH-R chemotherapy regimen
por: Lee, Yee Mei
Publicado: (2015)

Radiation therapy in primary mediastinal large B‐cell lymphoma treated with DA‐R‐EPOCH
por: Gentille, Cesar, et al.
Publicado: (2020)

Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2020)

CCND2 mRNA Expression Is Correlated With R-CHOP Treatment Efficacy and Prognosis in Patients With ABC-DLBCL
por: Wang, Di, et al.
Publicado: (2020)

PB2325: VALIDATION OF THE TRAIL SCORE TO PREDICT TOXICITY IN PATIENTS WITH DLBCL RECEIVING R-CHOP-LIKE THERAPY
por: Caballero, Juan Carlos, et al.
Publicado: (2023)

Allogeneic stem cell transplantation in acute myeloid leukemia
por: Ali, Natasha, et al.
Publicado: (2012)

Frequency and Outcome of Graft versus Host Disease after Stem Cell Transplantation: A Six-Year Experience from a Tertiary Care Center in Pakistan
por: Ali, Natasha, et al.
Publicado: (2013)

Outcome of donor and recipient sex match versus mismatch in stem cell transplant procedure
por: Ali, Natasha, et al.
Publicado: (2019)

Determinants of domestic violence among women of reproductive age (15–49 years) in Quetta, Balochistan—a mixed-method protocol
por: Soomar, Salman Muhammad, et al.
Publicado: (2022)

PB2301: OPTIMAL DOSE INTENSITY OF R-CHOP FOR PATIENTS WITH DLBCL AGED 80 YEARS OR OLDER: IS THE R-MINICHOP A GOLD STANDARD?
por: Nukariya, Hironao, et al.
Publicado: (2023)

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies
por: Zahid, Mohammad Faizan, et al.
Publicado: (2014)

Rituximab exposure‐response in triweekly R‐CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes
por: Liu, Shu, et al.
Publicado: (2021)

PB2134: THE ROLE OF ADDITIONAL CARBOGEN GAS MIXTURE AND NICOTINAMIDE ON R-CHOP CHEMOTHERAPY IN DLBCL PATIENTS WITH TUMOR HYPOXIA
por: Rizky, D., et al.
Publicado: (2022)

Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma
por: Dodero, A., et al.
Publicado: (2019)

P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
por: Zhu, H., et al.
Publicado: (2022)

Triple Expressor Lymphoma: Presentation With Acute Paraparesis Due to Spinal Cord Compression
por: Alburqueque-Melgarejo, Joseph, et al.
Publicado: (2022)

“Women are again unsafe”: Preventing violence and poor maternal outcomes during current floods in Pakistan
por: Soomar, Sarmad Muhammad, et al.
Publicado: (2023)

Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011
por: Ali, Natasha, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1ti03r808ip3iqqnnhu5els3am